ABSTRACT
Rationale Inhaled antimicrobials enable high local concentrations where needed and, compared to orally administration, greatly reduce the potential for systemic side effects. In SARS-CoV-2 infections, hydroxychloroquine (HCQ) administered as dry powder via inhalation could be safer than oral HCQ allowing for higher and therefore more effective pulmonary concentrations without dose limiting toxic effects.
Objectives To assess the local tolerability, safety and pharmacokinetic parameters of HCQ inhalations in single ascending doses of 5, 10 and 20 mg using the Cyclops dry powder inhaler.
Methods 12healthy volunteers were trained in inhaling HCQ correctly. Local tolerability and safety were assessed by pulmonary function tests, ECG and recording adverse events. To estimate systemic exposure, serum samples were collected before and 0.5, 2 and 3.5 h after inhalation.
Results and discussion Dry powder HCQ inhalations were well tolerated by the participants, except for transient bitter taste in all participants and minor coughing irritation. There was no significant change in QTc-interval or drop in FEV1 post inhalation. The serum HCQ concentration remained below 10 µg/L in all samples.
Conclusion Inhaled dry powder HCQ is safe and well tolerated. Our data support further studies with inhaled HCQ dry powder to evaluate pulmonary pharmacokinetics and efficacy is warranted.
Competing Interest Statement
YdR: no conflicts of interest PH: The employer of PH has a royalty agreement with AstraZeneca on the sales of the Genuair Inhaler; In addition, PH has a patent WO2015NL50413 20150605 licensed. MS: no conflict of interest FG: FG is employed by PureIMS, the manufacturer of the Cyclops inhaler. MB: no conflicts of interest IS: no conflicts of interest HK: no conflict of interest EF: The employer of HWF has a license agreement with PureIMS on the Cyclops patent (WO2015/187025) OA: no conflicts of interest
Clinical Trial
NCT04497519
Funding Statement
The production, labelling and distribution of the HCQ dry powder Cyclops inhalers was provided free of charge by PureIMS. All other funding was supplied by the institutions of the participating authors at University of Groningen and University Medical Center Groningen
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local medical ethical review committee (METc UMCG, Groningen, The Netherlands, METc number 2020.168).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available, however some restrictions will apply. Requests can be sent to the ethical board